Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.24.1.u1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Revenues $ 478,584 $ 603,359 $ 568,704
Cost of revenues 331,466 375,877 271,817
Amortization of intangible assets 428,431 428,431
Gross loss (profit) (147,118) 200,949 131,544
Operating expenses:      
Research and development 685,571 705,646 783,665
Less - research and development grants (405,268) (437,045) (315,967)
Research and development, net 280,303 268,601 467,698
Sales and marketing 393,785 566,896 625,031
General and administrative 1,415,632 1,893,179 1,345,495
Intangible asset impairment 2,108,117
Total operating expenses 2,089,720 4,836,793 2,438,224
Operating loss 1,942,602 5,037,742 2,569,768
Financial expenses (income), net (Note 13) 129,395 (528,195) (50,904)
Net loss $ 2,071,997 $ 4,509,547 $ 2,518,864
Net loss per ordinary share:      
Basic net loss per ordinary share (in Dollars per share) $ 0.01 $ 0.03 $ 0.06
Weighted average number of ordinary shares used in computing basic net loss per ordinary share (in Shares) 166,853,058 129,144,562 44,453,153